Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib in Immune Thrombocytopenia
NCT06721013Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised trial of pirtobrutinib in immune thrombocytopenia (ITP) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 4 weeks, Dose Limiting Toxicity (DLT) of Pirtobrutinib at 4 weeks and 4 more. Started Jul 2025; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06721013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721013.